Ergothioneine international congress 2011 to be held at UCLA

OXIS International, Inc., (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced that the "First International Congress on Ergothioneine, Anti-Oxidants, and Age Management Medicine" will be held Friday to Sunday, July 15-17, 2011, in the DeNeve Auditorium at the University of California, Los Angeles.

In addition to the specific dates and venue, OXIS announced that the keynote speaker on Saturday the 16th will be Steven G. Clarke, Ph.D., Professor of Biochemistry at UCLA and Director, UCLA Molecular Biology Institute.

"We are very pleased to have Dr. Clarke deliver the keynote speech at this important meeting on Ergothioneine," said Bernie Landes, president of OXIS International.  "He is a leader in the research on aging and rejuvenation, and will provide excellent background and context to the event's discussions of Ergothioneine and oxidative stress."

The Congress is being organized by OXIS' distinguished Science Advisory Board (SAB).  In addition to the keynote address, members of the SAB will make presentations focusing on their specific areas of expertise relating to Ergothioneine, including:

  • Dr. Okezie Aruoma, President of the OXIS SAB and founding faculty member of the Tuoro School of Pharmacy, discussing the latest research on the biochemistry of Ergothioneine and its relationship to key chronic disease states, including diabetes, cardiovascular disease, cancer and arthritis.  
  • Dr. John Repine, Director of the Webb-Waring Institute at the University of Colorado, a leading center for the study of oxidative stress related conditions, presenting the latest clinical research regarding the use of powerful new antioxidants, including Ergothioneine, in developing novel approaches to prevention and treatment.  
  • Dr. Steven Coles, a world authority on healthy aging and extreme longevity delivering the latest related findings in these increasingly important areas of research.

OXIS International is also now soliciting submissions for presentations at the Congress, which should be sent to [email protected]

OXIS plans to provide further details regarding the event, including registration information, in early 2011.


OXIS International, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests